AUGMENTATION OF ANGIOTENSIN II RELEASE FROM ISOLATED MESENTERIC ARTERIES OF WISTAR-KYOTO AND SPONTANEOUSLY HYPERTENSIVE RATS FOLLOWING NEPHRECTOMY

1. We previously reported that angiotensin II release from the mesenteric arteries of Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) increased in a time-dependent manner as a result of the isolation of the arteries and perfusion. This phenomenon appeared to be due to the withdrawal of circulating angiotensin II (AII). 2. The purpose of the present study was to test the hypothesis that vascular AII generation may be negatively regulated by circulating AII in WKY and SHR, and to clarify the role of this vascular angiotensin II in the sustained hypertension of SHR following nephrectomy. 3. The mesenteric arteries from kidney-intact and nephrectomized WKY and SHR were perfused and the amount of AII released into the perfusate was measured. The effects of the angiotensin converting enzyme inhibitor, captopril, and the effects of supplementation of renal renin and circulating angiotensins to nephrectomized rats, by blood exchange between kidney-intact and nephrectomized rats, on AII release were examined to clarify the pathway of vascular AII generation after nephrectomy. 4. Nephrectomy caused augmentation of vascular AII release both in WKY and SHR in spite of the abolishment of circulating renin. Captopril reduced this enhanced release of AII, but blood exchange did not affect it. There was no significant difference in these responses between WKY and SHR. 5. These results suggest that WKY and SHR have in common a potent pathway for production of vascular AII in response to the withdrawal of circulating AII, although this pathway is not responsible for the sustained hypertension of SHR after nephrectomy. The precise pathophysiological role of this pathway remains to be elucidated.     

肝癌病人血浆和癌组织中血栓调节蛋白的检测

目的　检测肝癌病人血浆和肝癌组织中血栓调节蛋白 (TM )的表达 ,探讨TM与肝癌临床病理特征的关系。方法　用酶联免疫吸附夹心法检测 45例肝癌和 6例肝良性占位病人手术前后的血浆TM水平 ;用免疫组织化学法检测肝癌及肝良性占位组织中的TM蛋白表达水平。结果　术前肝癌组血浆TM水平 ( 10 .2± 5 .7)ng/mL明显高于肝良性占位组 ( 6.1± 2 .2 )ng/mL和正常人对照组 ( 5 .7± 1.0 )ng/mL ,P <0 .0 5 ;术前TM血浆水平肝癌伴门静脉癌栓组 ( 6.9± 4.5 )ng/mL和多发肝癌结节组 ( 8.1± 4.6)ng/mL明显低于无门静脉癌栓组( 11.4± 5 .6)ng/mL和单发肝癌结节组 ( 11.5± 5 .9)ng/mL ,P <0 .0 5 ;40例肝癌病人肝癌切除术前TM水平( 10 .8± 5 .3 )ng/mL与肝癌切除术后 ( 7.6± 4.2 )ng/mL相比差异显著 ,P <0 .0 5。肝良性占位组术前与术后相比差异无显著性 ,P >0 .0 5。肝癌组织中TM蛋白表达阳性的病人术前血浆TM水平明显高于TM表达阴性者 ,P <0 .0 5 ;而术后血浆TM水平两者则无显著性差异 ,P >0 .0 5。结论　肝癌病人血浆中TM水平升高 ,TM水平的高低与门静脉癌栓的形成有关     

新改良式远端脾肾静脉分流术

本文报告一种新的改良式远端脾肾静脉分流术,即脾静脉与左肾静脉侧侧吻合、脾静脉远端结扎,再将胃冠状静脉结扎。作者经治7例,初步观察疗效较好,术后无死亡,无复发出血,无肝性脑病发生。本文对这种手术的步骤和优点进行了讨论和分析。     

原发性肝癌并发门静脉高压症的外科治疗

目的 :评价原发性肝癌并发门静脉高压症的外科治疗效果。方法 :回顾性分析联合手术治疗原发性肝癌并发门静脉高压症 30例的疗效。结果 :手术死亡 1例 ,严重肺部感染、肝肾综合征及顽固性腹水各 1例。术后 1、3、5年生存率分别为 93.3%、5 3.3%、40 %。随访中共死亡 1 7例 ,死亡原因 :肝癌复发 9例 ,肝功能衰竭 5例 ,上消化道出血 3例。结论 :理性选择联合手术方式治疗原发性肝癌并发门静脉高压症是安全可行的 ,联合行胃冠状静脉栓塞和脾切除术效果良好。     

高血压脑出血患者血肿周围血-脑屏障葡萄糖转运蛋白1表达的研究

目的观察高血压脑出血(ICH)患者血肿周围血-脑屏障葡萄糖转运蛋白1(GLUT1)表达的变化。方法采用免疫组化方法检测28例高血压ICH患者不同病程血肿周围脑组织GLUT1的表达情况。结果与对照组相比,ICH组发病12 h GLUT1表达开始增强,24 h、48 h表达最强(均P<0.01);72 h表达明显下降(P<0.01)。结论ICH早期血肿周围GLUT1表达增多,有助于恢复脑的能量代谢。     

食管癌贲门癌伴门脉高压症16例外科治疗分析

目的：分析16例食管癌贲门癌伴门脉高压症的围术期处理及外科治疗体会。方法：16例中根据肝功能Child分级A级11例，B级5例，其中3例行食管癌贲门癌根治同时行脾切除术。16例中6例行食管癌根治颈胃吻合术，3例行左侧副胸弓上食管胃吻合术，7例行弓下食管胃吻合术。结果：16例中1例死于肝性脑病，15例痊愈出院。术后并发症7例。其中3例同时行脾切除，病情改善明显。随访7个月至5年，失访3例；术后1、3、5年生存率分别是81.2％、56．2％及33．3％，无1例死于消化道出血。结论：对于食管癌贲门癌伴门脉高压症患者手术是首选方法；改善肝功能、纠正低蛋白血症及脾功能亢进是关键，合并脾亢患者应同时行脾切除术。     

无创伤法联合测定门静脉压力及肝血流评价肝硬化疗效

目的　为临床评价肝硬化疗效提供有价值的手段。方法　采用99Tcm-RBC及99Tcm-MIBI分别测定 16例肝硬化患者治疗前后的肝血流及门静脉压力。前者选择峰时 (T(max) 、半廊清时 (T1/ 2 )、廊清率 (K值 )及肝血流(LBF)等作为观察指标 ;后者以心 /肝 (H/L)比值及门静脉压力 (PVP)为观察指标。结果　治疗前Tmax、T1/ 2 、K值及LBF分别为 1.83± 1.0 4min、5 .3 7± 2 .19min、0 .10± 0 .0 3及 0 .45± 0 .16L/min ,而治疗后分别为 0 .86± 0 .2 0min、3 .80± 1.86min、0 .14± 0 .0 4及 0 .64± 0 .2 0L/min ,治疗前后各项指标均有非常显著性差异 (P <0 .0 1或 0 .0 0 1)。服药前H/L、PVP分别为 0 .73± 0 .16及 3 .0 0± 0 .5 5kPa;治疗后分别为 0 .47± 0 .18及 2 .2 0± 0 .62kPa,与治疗前相比均有非常显著性差异 (均P <0 .0 0 1)。结论　所用测定肝血流及门静脉压力的两种方法均无创伤性 ,用于观察肝硬化疗效有一定价值     

三维重建单(双)靶点定向置管引流术治疗高血压壳核出血

目的回顾性分析三维重建单(双)靶点定向置管引流术治疗高血压壳核出血的疗效,验证该方法的有效性和可行性。方法将133例壳核脑出血病人的CT定位扫描资料输入计算机工作站,对血肿进行三维重建,根据血肿量的大小和形状设计1～2个靶点和引流管路径。应用立体定向技术将引流管(外径5mm,内径3mm)送至颅内预定靶点,术中应用10ml注射器轻柔抽吸血肿液化部分,术后将尿激酶(1～2万IU)注入血肿腔内,夹闭引流管2h后自然引流,每12h重复1次。复查CT证实剩余血肿量为最初的10%~15%时拔除引流管。结果平均置管1.5 d(1～3d),平均血肿排空率92.8%。术后1个月病死率6.0%,远期随访(平均22个月)病死率11.3%,优良率74.4%。结论该方法治疗高血压壳核脑出血,血肿排空较彻底,疗效可靠,尤其适用于血肿量较大(>25ml)且形态不规则的颅内血肿。